Roche inks $142M deal for prostate cancer drug; Solid Bio joins with UF on DMD work;

@FierceBiotech: China's WuXi raises a $290M VC fund with eyes on 'cross-border' biotech bets. Article | Follow @FierceBiotech

@JohnCFierce: The 'big' model doesn't work in drug R&D, unless you're doing a big, focused PhIII program. . Source drugs. Focus. Gamble smart. | Follow @JohnCFierce

@DamianFierce: The 2015 Biotech IPO Boom, in Requiem. Watch | Follow @DamianFierce

> Roche ($RHHBY) has in-licensed a new therapy for advanced prostate cancer developed by scientists from the University of British Columbia and the Vancouver Coastal Health Research Institute, agreeing to pay an undisclosed upfront and up to $141.7 million. "We're at a stage now that we need the right pharmaceutical partner to help to move this technology from a discovery into a finished product," said Paul Rennie, a professor in the department of Urologic Sciences at UBC and director of laboratory research at the Vancouver Prostate Centre. Release

> Solid Biosciences out of Cambridge, MA, has agreed to pay the University of Florida Powell Gene Therapy Center $2 million for work on a new therapy for Duchenne muscular dystrophy. Story

Medical Device News

@FierceMedDev: ICYMI yesterday: Cleveland Clinic-partnered low-cost MRI provider nabs $6.5M to kick off national expansion. Article | Follow @FierceMedDev

@EmilyWFierce: ICYMI Friday: Lab experts lash out at  move to beef up regulation of lab-developed tests. Article | Follow @EmilyWFierce

> Startup raises $5M to market next-gen nausea wearable to consumers. Article

> U.S., Israel commit $12M to develop next-gen tech for first responders. Story

> In latest Covidien deal synergy, Medtronic to build $14M manufacturing facility in Ireland. Report

Pharma News

@FiercePharma: China's Jiangsu Hansoh Pharmaceutical seeks $1.5B via HKEx IPO. FierceAsiaPharma story | Follow @FiercePharma

@EricPFierce: AstraZeneca closing Indian API plant that Swedish regulators slammed in an inspection report. FiercePharmaManufacturing story | Follow @EricPFierce

@CarlyHFierce: Roche challenges hometown rival Novartis with new targeted lung-cancer med Alecensa. More from FiercePharmaMarketing | Follow @CarlyHFierce

> FDA panel dashes Merck's hopes for broader use of Zetia, Vytorin. Report

> FDA avoids another free-speech ruling by cutting a deal with Pacira. Article

> Sanofi plots $12.5 billion Merial tradeoff with Boehringer, gaining consumer unit in the bargain. More

Pharma Manufacturing News

> AstraZeneca adding $113M packaging, warehouse facility in U.K. Report

> Sun Pharma shedding Ohio plant with sale to Nostrum Laboratories. Item

> Capsugel gets more manufacturing expertise with two-company deal. More

> Mylan wants some payback for plants it bought from Strides cited by FDA. Story

> Sweden says AstraZeneca used questionable asthma drug API from Indian plant. Article

Drug Delivery News

> Heat-enabled chemotherapy showing promise in studies. More

> More surgeons opt for spinal anesthesia in infants. Item

> Three-drug nanoparticle cuts back resistance in metastatic melanoma. Report

> Matinas' cochleate drug delivery candidate gets FDA's infectious disease product boost. Story

> Bind advances one arm of its lung cancer nanoparticle candidate, ditches another. Article

Pharma Asia News

> Fosun Group attempts to explain as high-profile chief detained by China authorities. Report

> China connection aids $280M in new funding for Pharmaron. Item

> China's Jiangsu Hansoh Pharmaceutical seeks $1.5B via HKEx IPO. Story

> As trade pacts sprout in Asia, medical device firms need to take note. Article

> Reckitt Benckiser ordered by Australian court to pull ibuprofen painkillers. More

Suggested Articles

Karen DeSalvo's appointment is the latest in a string of hires that deepen the tech giant’s investment in and focus on healthcare.

Spring Bank’s hepatitis B drug, given in tandem with Gilead’s Vemlidy, tamped down on chronic disease in 23% of patients in a phase 2 study.

Gilead names Dickinson to CFO role; MedImmune CSO Herbst nabs CSO job at Pyxis; Checkmate picks up Wooldridge for CMO.